细胞因子风暴综合征和细胞因子释放综合征的研究进展

刘亮; 孟圆; 高全立

doi:10.12354/j.issn.1000-8179.2022.20220141

细胞因子风暴综合征和细胞因子释放综合征的研究进展

doi: 10.12354/j.issn.1000-8179.2022.20220141

刘亮^1,,
孟圆¹,
高全立^2, ,

1.
天津医科大学肿瘤医院生物技术研究室，天津医科大学肿瘤医院生物治疗科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津市肿瘤免疫与生物治疗重点实验室（天津市300060）
2.
郑州大学附属肿瘤医院，河南省肿瘤医院免疫治疗科

基金项目: 本文课题受国家自然科学基金项目（编号：U20A20375、81872166）资助

详细信息

作者简介:
刘亮：专业方向为肿瘤免疫、肿瘤干细胞和肿瘤耐药

通讯作者:
高全立　zlyygql0855@zzu.edu.cn

计量
- 文章访问数: 721
- HTML全文浏览量: 87
- PDF下载量: 149
- 被引次数: 0
出版历程
- 收稿日期: 2022-01-25
- 录用日期: 2022-03-04
- 修回日期: 2022-03-01
- 网络出版日期: 2022-06-27

Research progress in cytokine storm syndrome and cytokine release syndrome

Liang Liu^1
,,
Yuan Meng¹,
QuanLi Gao^{2
, ,}

1.
Department of Immunology and Biotherapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Immunology and Biotherapy, Tianjin 300060, China
2.
Immunotherapy Department, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 40052, China

Funds: This work was supported by the National Natural Science Foundation of China (No. U20A20375, No. 81872166)

More Information

Corresponding author: QuanLi Gao; E-mail: zlyygql0855@zzu.edu.cn

摘要

摘要: 细胞因子风暴（cytokine storm，CS）是一种累及全身的系统性炎症反应，可由多种诱因导致，由其发展的疾病包括细胞因子风暴综合征（cytokine storm syndrome，CSS）和细胞因子释放综合征（cytokine release syndrome，CRS）。其中CSS与感染和自身免疫性疾病等有关，而CRS与肿瘤免疫治疗的不良反应有关。目前医学工作中，对CSS和CRS认识不足，两者概念极易混淆。随着肿瘤免疫检查点抑制剂和免疫细胞治疗的广泛应用，CRS在临床上越来越常见。因此，迫切需要提高对CSS和CRS的正确诊断和认识，有助于对其临床和基础研究提供进一步的帮助。本文分别介绍了CSS和CRS各自的发展历史、分类及发生机制等，旨在为CSS和CRS的诊断、鉴别诊断、预防和治疗提供帮助。
- 细胞因子 /
- 细胞因子风暴 /
- 细胞因子风暴综合征 /
- 细胞因子释放综合征 /
- 不良反应
Abstract: Cytokine storm (CS) is an inflammatory response involving the whole body and has a variety of causes. CS-associated diseases include cytokine storm syndrome (CSS) and cytokine release syndrome (CRS). CSS involves infections and autoimmune diseases, and CRS is related to the adverse reactions of tumor immunotherapy. The understanding of CSS and CRS is incomplete. The two concepts are easily confused, especially in terms of treatment that extensively involves tumor immune checkpoint inhibitors and immune cell therapy. CRS is becoming increasingly common in clinical practice. Therefore, the correct diagnosis and understanding of CSS and CRS are crucial aspects in clinical and basic research. This review discusses the development history, classification, and mechanism of CSS and CRS. The aim is to aid the diagnosis, differential diagnosis, prevention, and treatment of CSS and CRS.
- cytokine /
- cytokine storm (CS) /
- cytokine storm syndrome (CSS) /
- cytokine release syndrome (CRS) /
- adverse reactions

HTML全文

参考文献(33)

[1]	王玉亮,王峰,耿洁.细胞因子与细胞因子风暴[J].天津医药,2020,6(48):494-498.
[2]	Farquhar JW, Claireaux AE. Familial haemophagocytic reticulosis[J]. Arch Dis Child, 1952, 27(136):519-525. doi: 10.1136/adc.27.136.519
[3]	Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1[J]. Transplant Proc, 1993, 25:1216-1217.
[4]	Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome[J]. Clin Exp Immunol, 2004, 136(1):95-103. doi: 10.1111/j.1365-2249.2004.02415.x
[5]	Yuen KY, Wong SS. Human infection by avian influenza A H5N1[J]. Hong Kong Med J, 2005, 11(3):189-199.
[6]	Murdaca G, Paladin F, Tonacci A, et al. The potential role of cytokine storm pathway in the clinical course of viral respiratory pandemic[J]. Biomedicines, 2021, 9(11):1688. doi: 10.3390/biomedicines9111688
[7]	Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids[J]. Transplantation, 1990, 49(4):697-702. doi: 10.1097/00007890-199004000-00009
[8]	Eastwood D, Findlay L, Poole S, et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells[J]. Br J Pharmacol, 2010, 161(3):512-526. doi: 10.1111/j.1476-5381.2010.00922.x
[9]	Rotz SJ, Leino D, Szabo S, et al. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy[J]. Pediatr Blood Cancer, 2017, 64(12): 10.1002/pbc. 26642.
[10]	Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med, 2014, 371(16):1507-1517. doi: 10.1056/NEJMoa1407222
[11]	Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells[J]. Biol Blood Marrow Transplant, 2019, 25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758
[12]	Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus[J]. Nature, 2003, 426(6965):450-454. doi: 10.1038/nature02145
[13]	Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X
[14]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5
[15]	陈蕾,刘辉国,刘威,等.2019新型冠状病毒肺炎29例临床特征分析[J].中华结核和呼吸杂志,2020,43(3):203-208. doi: 10.3760/cma.j.issn.1001-0939.2020.03.013
[16]	Zhang Y, Li J, Zhan Y, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome[J]. Infect Immun, 2004, 72(8):4410-4415. doi: 10.1128/IAI.72.8.4410-4415.2004
[17]	Zhou J, Chu H, Li C, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis[J]. J Infect Dis, 2014, 209:1331-1342. doi: 10.1093/infdis/jit504
[18]	Kim ES, Choe PG, Park WB, et al. Clinical progression and cytokine profiles of middle east respiratory syndrome coronavirus infection[J]. J Korean Med Sci, 2016, 31(11):1717-1725. doi: 10.3346/jkms.2016.31.11.1717
[19]	Risdall RJ, McKenna RW, Nesbit ME, et al. Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis[J]. Cancer, 1979, 44(3):993-1002. doi: 10.1002/1097-0142(197909)44:3<993::AID-CNCR2820440329>3.0.CO;2-5
[20]	Tang Y, Xu X, Song H, et al. Early diagnostic and prognostic signifcance of a specifc Th1/Th2 cytokine pattern in children with haemophagocytic syndrome[J]. Br J Haematol, 2008, 143:84-91. doi: 10.1111/j.1365-2141.2008.07298.x
[21]	Han XC, Ye Q, Zhang WY, et al. Cytokine profiles as novel diagnostic markers of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children[J]. J Crit Care, 2017, 39:72-77. doi: 10.1016/j.jcrc.2017.02.018
[22]	Mazodier K, Marin V, Novick D, et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome[J]. Blood, 2005, 106(10):3483-3489. doi: 10.1182/blood-2005-05-1980
[23]	Chen Y, Wang Z, Luo Z, Zhao N, Yang S, Tang Y. Comparison of Th1/Th2 cytokine profiles between primary and secondary haemophagocyticlymphohistiocytosis[J]. Ital J Pediatr, 2016, 42(1):50. doi: 10.1186/s13052-016-0262-7
[24]	Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia[J]. N Engl J Med, 2018, 378:449-459. doi: 10.1056/NEJMoa1709919
[25]	Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma[J]. N Engl J Med, 2020, 382:1331-1342. doi: 10.1056/NEJMoa1914347
[26]	HAY K A, HANAFI L A, LI D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy[J]. Blood, 2017, 130(21):2295-2306. doi: 10.1182/blood-2017-06-793141
[27]	Marofi F, Al-Awad AS, Sulaiman Rahman H, et al. CAR-NK Cell: A new paradigm in tumor immunotherapy[J]. Front Oncol, 2021, 11:673276. doi: 10.3389/fonc.2021.673276
[28]	Ciurea SO, Schafer JR, Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation[J]. Blood, 2017, 130(16):1857-1868. doi: 10.1182/blood-2017-05-785659
[29]	Vezys V, Penaloza-MacMaster P, Barber DL, et al. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection[J]. J Immunol, 2011, 187(4):1634-1642. doi: 10.4049/jimmunol.1100077
[30]	Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormalmacrophage activation and ameliorated with cytokine-directed therapy[J]. Blood, 2013, 121:5154-5157. doi: 10.1182/blood-2013-02-485623
[31]	Urasaki T, Ono M, Mochizuki T, et al. Case report: acase of trimethoprim/sulfamethoxazole-triggered hypotensive shock: cytokine release syndrome related to immune checkpoint inhibitors and drug-induced hypersensitivity syndrome[J]. Front Oncol, 2021, 11:681997. doi: 10.3389/fonc.2021.681997
[32]	Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome[J]. Blood, 2016, 124(2):188-195.
[33]	Oda H, Ishihara M, Miyahara Y, et al. First case ofcytokine release syndrome after nivolumab for gastric cancer[J]. Katayama N Case Rep Oncol, 2019, 12(1):147-156. doi: 10.1159/000496933